Featured

Status

Health Topics

Any Category
Diseases
Neoplasms
Neoplasms by Site
Clear Filters

Search Clinical Trials

35 Results
Terminated
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Avelumab is a fully human monoclonal PD-L1 antibody of the immunoglobulin G1 (IgG1) subclass. It works by binding to PD-L1 on tumor cells, immune cells and/or stromal cells. This prevents …
Baylor Role: Lead Sponsor
Recruiting
Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade
Non-invasive bladder cancer is challenging to treat because it is a condition characterized by frequent recurrences that lead to numerous invasive procedures for detection and treatment. The mainstay of therapy …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib …
Baylor Role: Lead Sponsor
Active, Not Recruiting
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
HPV is found in the cancer cells of more than half the patients with certain types of cancer, suggesting that it may play a role in causing the cancer. The …
Baylor Role: Lead Sponsor
Completed
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Patients with primary or recurrent low/intermediate-risk papillary urothelial carcinoma of the bladder will undergo resection of all but one marker lesion, measuring at least 6mm but no greater than 10mm, …
Baylor Role: Lead Sponsor
Withdrawn
Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Men who participate in this study will take both metformin and simvastatin every day. Both drugs are pills and can be taken at home. Subjects will be asked to take …
Terminated
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Everolimus has significantly improved outcomes following prior therapy. This study is a biomarker driven Phase II trial that will assess the activity of everolimus as first-line therapy for renal cell …
Completed
Prostate Cancer Symptom Management for Low Literacy Men
Prostate cancer has recently surpassed lung cancer to become the most common cancer of American men. The estimated number of new prostate cancer cases in 2005 is expected to be …
Baylor Role: Lead Sponsor
Completed
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
Patients will be screened within 6 weeks prior to Week 1. A total of 3 cohorts, consisting of 3 to 6 patients each, are planned to receive five to eight …
Baylor Role: Collaborator
Completed
Health-Related Quality of Life in Gay Men With Localized Prostate Cancer
OBJECTIVES: - To enroll 200 gay men with localized prostate cancer in a cross-sectional study of prostate cancer outcomes. - To complete an R01 application using pilot data collected from …
Baylor Role: Lead Sponsor